Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
Stopped early · Phase 3
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
Key facts
- Study ID
- NCT00004227
- Run by
- University of Alabama at Birmingham
- People needed
- 32
- Starts
- 1999-04-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2014-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kimball Medical Center — Lakewood, New Jersey, United States
- Monmouth Medical Center — Long Branch, New Jersey, United States
- ImClone Systems, Incorporated — Somerville, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.